-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10

Benzinga·02/04/2026 16:04:05
Listen to the news
Cantor Fitzgerald analyst Olivia Brayer maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $6 to $10.